This article is the second part in a series where we examine the best way to drive brand growth and the market research approaches needed to support it.

This short article is the first part in a series where we examine the best way to drive brand growth and the market research approaches needed to support it.

Have you ever wondered what the best way is to drive the growth of your brand? At Purdie Pascoe, we have been looking into this, from a market research viewpoint, starting with a determination to be led by science rather than unfounded theories.

Many of the projects we do at Purdie Pascoe involve pricing or even have pricing as the principal objective. Our clients are constantly coming up with great new products, or improvements to existing ones, and they want to know if people will pay for them.

4th Medical Devices Regulatory and Compliance Online Summit (Vonlanthen Group)

Post market clinical follow-up (PMCF) surveys:

‘The ever-changing landscape’

Date: 24 - 25 March, 2022

Location: Virtual / Zoom

Doctors hate marketing. They’re always telling us that. They’re only interested in cold, hard evidence, not catchy slogans, or pictures of hopeful looking patients. Give us the facts, they say, don’t shower us in sentiment. Or (surely one of the most frustrating things for a marketeer to hear) “just make it less marketing-y”. But… we all know that underneath those white coats they’re just human beings like you and me.

One of the key aims for market researchers is to help our clients truly understand how their customers make decisions, and to identify and ideally quantify the most important choice drivers. Conjoint is one of our key tools for doing this.

Decentralized clinical trials have become the new normal during Covid times, and many advocate for this novel approach to grow into the industry standard. The days of solely focusing on key large centres for patient accrual are over, and this shift in paradigm can only benefit a greater number of cancer patients, everywhere.

Companion diagnostics (CDx) and laboratory diagnostic tests are key components of the patient pathway, especially in oncology. While the importance of biomarker testing and tumor profiling is more and more accepted by the medical community, few pharma and diagnostic companies have a solid handle on what drives testing behaviors.

As market researchers, we are frequently asked to identify the key drivers of a market, including prescribing or purchase behaviour. As human beings, we are often unaware of exactly what leads us to make certain decisions, so to focus on stated importance is flawed. Instead, we need to statistically derive the importance of key drivers, by assess correlations between different data points.

In your role, do you ever need to present geographical differences in data, either within a country or across countries? Excel spreadsheets or huge tables capture this information, but in a very dull, uninspiring way. A Heat Map could be the data visualisation tool that you are looking for.

Do you ever need to present large quantities of longitudinal data in a way that is digestible and engaging? Are you and your colleagues sick of static PowerPoint slides that represent one point in time but fail to effectively communicate insights over time? A bar chart race might be the answer.

New award-winning analysis of Coronavirus cases and deaths by English regions has found that areas with high risk of personal and material victimisation , income deprivation among under 60s and low skills and attainment suffered higher death rates from COVID-19. Significantly, areas with high proportions of non-whites and over 70s also had higher deaths per head of population when controlling for other relevant factors.

On Monday, 10th May, the BHBIA held their annual Best of Business Intelligence awards, aka The BOBI awards. We were delighted to win Analyst Team of the Year, in partnership with our friends at The Stats People, for our analysis of UK and International COVID-19 data.

New analysis of Coronavirus cases and deaths by country has found that countries with tougher government Covid stringency measures had a higher number of Covid cases and deaths per head of population than those with less stringent measures, even after controlling for age and relevant health differences.

Both the EU Medical Device Regulation (EU MDR) and the EU In-Vitro Diagnostics Regulation (IVDR) are new and updated sets of regulations, following on from the Medical Device Directive (MDD) and the In-Vitro Diagnostics Directive (IVDD) respectively. The EU-MDR comes into force in May 2021, while the IVDR follows a year later in May 2022.

Back in October, Guy Pascoe wrote about the increase in webcam interviewing during COVID. Six months later, he’s back with an update.

For our third blog in the series, I have been joined by our friend and partner, Gary Bennett, from The Stats People, to talk about targeting and segmentation, and more specifically how to improve the effectiveness of your marketing through a segmentation approach that works.

5 top tips for pharma companies to develop delivery devices that make a difference to patients and healthcare professionals.

In the 1990s, when I started in healthcare market research, successful pharma launches were built on strong clinical profiles. Blockbusters like Lipitor, Prozac and Losec succeeded on the basis of their superior clinical data. Huge salesforces then took this data to as many doctors as possible to persuade them of the value of their product…and huge sales followed.

The EU Medical Device Regulation (EU MDR) is a new and updated set of regulations, following on from the Medical Device Directive (MDD), that will now come into force on May 26, 2021.